Business Description
![Merck & Co Inc Merck & Co Inc logo](https://static.gurufocus.com/logos/0C000008C5.png?14)
Merck & Co Inc
NAICS : 325412
SIC : 2834
ISIN : US58933Y1055
Compare
Compare
Traded in other countries / regions
MRK.USAMRCK34.BrazilMRK.MexicoMRK.ArgentinaMRK.Chile6MK.GermanyMRK.Peru1MRKX.ItalyMRK.Austria6MKd.UKMRK.FranceMRK.Ukraine IPO Date
1946-06-15Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 0.85 | |||||
Debt-to-EBITDA | 3.81 | |||||
Interest Coverage | 4.07 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.5 | |||||
Beneish M-Score | -2.99 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13 | |||||
3-Year EBITDA Growth Rate | -12.2 | |||||
3-Year EPS without NRI Growth Rate | -20.2 | |||||
3-Year FCF Growth Rate | 16.1 | |||||
3-Year Book Growth Rate | 14.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 83.79 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.81 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.25 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 142.81 | |||||
Days Sales Outstanding | 63.67 | |||||
Days Payable | 83.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Payout Ratio | 1.37 | |||||
3-Year Dividend Growth Rate | 6.1 | |||||
Shareholder Yield % | 1.44 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 74.37 | |||||
Operating Margin % | 7.99 | |||||
Net Margin % | 3.76 | |||||
FCF Margin % | 18.12 | |||||
ROE % | 5.63 | |||||
ROA % | 2.17 | |||||
ROIC % | 3.79 | |||||
ROC (Joel Greenblatt) % | 20.67 | |||||
ROCE % | 6.22 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 140.5 | |||||
Forward PE Ratio | 14.64 | |||||
PE Ratio without NRI | 58.27 | |||||
Shiller PE Ratio | 35.72 | |||||
PS Ratio | 5.24 | |||||
PB Ratio | 7.93 | |||||
Price-to-Tangible-Book | 198.82 | |||||
Price-to-Free-Cash-Flow | 29.14 | |||||
Price-to-Operating-Cash-Flow | 21.79 | |||||
EV-to-EBIT | 68.19 | |||||
EV-to-Forward-EBIT | 11.73 | |||||
EV-to-EBITDA | 38.85 | |||||
EV-to-Forward-EBITDA | 10.26 | |||||
EV-to-Revenue | 5.68 | |||||
EV-to-Forward-Revenue | 4.83 | |||||
EV-to-FCF | 31.6 | |||||
Price-to-Projected-FCF | 2.26 | |||||
Price-to-Median-PS-Value | 1.21 | |||||
Price-to-Graham-Number | 22.68 | |||||
Earnings Yield (Greenblatt) % | 1.47 | |||||
FCF Yield % | 3.45 | |||||
Forward Rate of Return (Yacktman) % | 1.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merck & Co Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 56,762.409 | ||
EPS (TTM) (€) | 0.854 | ||
Beta | 0.14 | ||
Volatility % | 1.18 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 101.4 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 101.4 - 101.4 | ||
Shares Outstanding (Mil) | 2,532.81 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Merck & Co Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Merck & Co Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Merck & Co Inc Frequently Asked Questions
What is Merck & Co Inc(XPAR:MRK)'s stock price today?
The current price of XPAR:MRK is €101.40. The 52 week high of XPAR:MRK is €101.40 and 52 week low is €101.40.
When is next earnings date of Merck & Co Inc(XPAR:MRK)?
The next earnings date of Merck & Co Inc(XPAR:MRK) is 2024-07-30.
Does Merck & Co Inc(XPAR:MRK) pay dividends? If so, how much?
Merck & Co Inc(XPAR:MRK) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |